Vaccine Market Access in 100 Days: From Pipe Dream to Reality
Many factors contribute to delays in vaccine market access including, but not limited to, poorly transparent National Immunization Technical Advisory Group (NITAG) processes and requirements, time-consuming evidence-generation requirements, and gaps and uncertainties in the evidence base.
We have launched a “100 days to vaccine market access” initiative to help vaccine manufacturers submit NITAG/HTA packs within 100 days of marketing authorization. Our recommendations focus on the implementation of a three-pillar framework, which can be used to address HTA/NITAG submission requirements and overcome challenges across the vaccine life cycle.
What you will learn in this white paper:
- Strategies to expedite patient access to vaccines
- Insights to overcome barriers to timely vaccine market access
- Our three-pillar strategy for successful evidence generation across the vaccine life cycle
